Educational Symposium
Advances in Treatment and Management of FSGS
October 22, 2026 | 12:45 PM - 01:45 PM
Location: TBD Room, Hyatt Regency Denver
Session Description
FSGS is a progressive glomerular disease in which persistent proteinuria is the dominant clinical manifestation and a major driver of kidney failure risk. Despite guideline-recommended supportive care, including renin-angiotensin system inhibition, blood pressure control, and selective immunosuppression, many patients do not achieve sustained remission, and a substantial proportion progress to kidney failure within 10 years. Nonspecific immunosuppression, such as glucocorticoids and calcineurin inhibitors, carry significant toxicity. Advances in podocyte biology, including hemodynamic, inflammatory, cytoskeletal, and APOL1-related pathways, have led to development of targeted, nonimmunosuppressive therapies. The US Food and Drug Administration approved sparsentan in April 2026 as the DUPLEX trial data demonstrated greater sustained proteinuria reduction compared to irbesartan, reinforcing proteinuria as a meaningful therapeutic target and providing a new treatment option for patients.
This symposium presents a case-based, evidence-driven, "proteinuria-first" strategy for FSGS in adults. Experts review how to define proteinuria targets; apply a treat-to-target approach; and tailor therapy based on etiology, severity, and patient factors. Sequencing of supportive care, immunosuppression, and emerging targeted therapies; monitoring response; and adjusting treatment over time are also discussed. Participants are provided with a structured framework to reduce proteinuria and mitigate the risk of kidney failure as the FSGS landscape evolves.
Seating is limited and available on a first-come, first-served basis to fully paid Annual Meeting participants. Doors open approximately 15 minutes prior to each symposium. When a room reaches capacity, ASN will shut down access to the room. No other participants will be allowed to enter the room, regardless of the number of participants who exit the room during the activity.
Support is provided by an educational grant from Travere Therapeutics, Inc.
Learning Objective(s)
- Define the importance of proteinuria as a driver of disease in FSGS and its potential to accelerate approval of novel therapies
- Summarize emerging approaches to address the mechanisms driving eGFR loss in FSGS
- Evaluate large-scale analyses from the PARASOL Project
Learning Pathway(s)
- Glomerular Diseases
- CKD Non-Dialysis
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Proteinuria as a Surrogate for Kidney Failure Risk in FSGS
12:55 PM - 01:15 PM
- Selecting and Sequencing Therapy for FSGS: Past, Present, and Future
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM